Author

U. Schmitz

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 4 Approach:experimental assay· 3 Assay:proteomics· 2 Approach:benchmark study· 1 Research Focus:benchmarking· 1 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1

Frequent Co-Authors

A. Cano-Galiano· 1 shared A. Lanas· 1 shared A. Y. Au· 1 shared B. Feierbach· 1 shared B. Parejo-Alonso· 1 shared B. Sainz· 1 shared C. G. Bailey· 1 shared C. H. Tay· 1 shared

Activity by Year

2021-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 12 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Cano-Galiano

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Characterization of a KDM5 Small Molecule Inhibitor with Antiviral Activity against Hepatitis B Virus

U. Schmitz, S. A. Gilmore, D. Tam, T. L. Cheung, C. Snyder, J. Farand, R. Dick, M. Matles, J. Y. Feng, R. Ramirez, L. Li, H. Yu, Y. Xu, D. Barnes, G. Czerwieniec, , B. Feierbach

This study identifies a KDM5 inhibitor with anti-HBV activity in vitro but not in vivo, highlighting challenges in translating epigenetic therapies to viral infections.

bioRxiv · Jun 27, 2022 · PreprintPharmacology & Toxicology

Towards resolution of the intron retention paradox in breast cancer

J. S. Shah, M. Milevskiy, V. Petrova, A. Y. Au, J. J. L. Wong, J. E. Visvader, U. Schmitz, J. E. J. Rasko

This study investigates intron retention (IR) patterns in breast cancer and other cancers, finding that reduced IR in breast tumors correlates with poor prognosis and is linked to factors like cell proliferation and RBP expression.

bioRxiv · Mar 4, 2022Cancer Biology

PPAR-delta acts as a metabolic master checkpoint for metastasis in pancreatic cancer

B. Parejo-Alonso, D. Barneda, S. M. Trabulo, S. Courtois, S. Compte-Sancerni, L. Ruiz-Canas, Q. Zheng, J. Tang, M. Chen, Z. Guo, U. Schmitz, P. Irun, L. Penin-Peyta, S. M. Crusz, A. Cano-Galiano, , P. Sancho

This study shows PPAR-delta drives metabolic reprogramming in pancreatic cancer, promoting metastasis, and its inhibition reduces invasiveness.

bioRxiv · Nov 15, 2021 · PreprintCancer Biology

Somatic mutations in CTCF zinc fingers produce cellular phenotypes explained by structure-function relationships

J. E. Rasko, C. G. Bailey, S. Gupta, C. Metierre, P. Amarasekera, P. O'Young, W. Kyaw, T. Laletin, H. Francis, C. Semaan, K. Singh, C. Mullighan, O. Wolkenhauer, U. Schmitz

This study identifies somatic CTCF mutations in cancer and shows how their structure-function relationships affect cellular phenotypes and tumour suppressor function.

bioRxiv · Jan 8, 2021Cancer Biology